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ABSTRACT 
  
The  condition accompanying  depression  will  always be  progressing into poor  prognosis if the 
depression itself is not recognized and treated properly. Among diabetic patients, depression was 
associated with increased mortality and  poor quality of life . It was observed that diabetes and 
depression has a bidirectional relationship, where the clinical course of both conditions are affecting each 
other. Despite the effectiveness of psychological and psychopharmacological interventions in treating 
depressive symptoms in diabetic patients, the effect of such interventions on glycemic control is still 
inconsistent. Complementary alternative medicine (CAM) alone or in combination with standard medical 
treatment, targeting both depression and diabetes, appears to be promising. Latihan Pasrah Diri (LPD) has 
been recognized as a type of relaxation technique under CAM. It is initially directed to provide adequate 
relieve of depression using both religious and relaxative approach. Among patients with comorbid diabetes 
and depression, this approach has long been known and utilized over the counter, but its formal practice 
is seldom advocated, whereas, many clinical trials has been conducted locally to reveal its potential use. 
Combined with standard therapy, LPD is expected to show its beneficial effects. 
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ABSTRAK 
 
Kondisi yang menyertai depresi akan selalu berlanjut menjadi prognosis buruk jika depresi itu sendiri 
tidak dikenali dan diobati dengan baik. Di antara pasien diabetes, depresi dikaitkan dengan peningkatan 
angka kematian dan kualitas hidup yang buruk. Diobservasi bahwa diabetes dan depresi memiliki 
hubungan dua arah, di mana perjalanan klinis kedua kondisi tersebut saling mempengaruhi. Terlepas dari 
efektivitas psikoterapi, efek dari intervensi kontrol glikemik tersebut masih tidak konsisten. Pengobatan 
alternatif komplementer (CAM) sendiri atau dikombinasikan dengan pengobatan standar, yang 
menargetkan depresi dan diabetes, tampaknya menjanjikan. Latihan Bela Diri (LPD) telah dikenali 
sebagai jenis teknik relaksasi di bawah CAM. Ini pada awalnya diarahkan untuk memberikan bantuan 
depresi yang memadai dengan menggunakan pendekatan religius dan relaksasi. Di antara pasien diabetes 
komorbid dan depresi, pendekatan ini telah dilakukan dan jarang dianjurkan, sedangkan banyak uji klinis 
telah dilakukan secara lokal untuk mengungkapkan potensi penggunaannya. Dikombinasikan dengan 
terapi standar, LPD diharapkan dapat menunjukkan efek menguntungkannya. 
 
Kata kunci: depresi, diabetes, pengobatan alternatif komplementer, latihan self-absorption
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A. Introduction 
 
Depression is common in diabetes and has 
been shown to cause detrimental medical 
outcomes. The field of research to find 
treatment that consistently leads to better 
medical outcomes in patients with both 
depression and diabetes is still widely open. 
LPD was introduced to complement 
psychological and  psychopharmacological  
therapy in  this area.  This review provides 
brief insight of  recently published, 
randomized  
 
controlled trials (RCTs) on the treatment 
of depression in diabetic patients, revisiting 
LPD as a novel therapeutic modality under 
CAM. 
 
 
Mapping the Problem 
 
The  prevalence of depression is 2–3  
times higher in people with diabetes than  in 
the  general population with approximately 
10% of diabetes patients have major 
depression (1). The fact that adults with 
depression have also an increased risk of 
developing type 2 diabetes (37% increased risk) 
(2), leave us to conclude that there is a 
bidirectional association between depression 
and diabetes (3, 
4). The mechanisms behind this association 
is unclear. In one direction, at least three 
hypothesis have been proposed, including: 
depression resulting from the psychosocial 
burden of living with diabetes; depression 
resulting from biochemical changes related to 
diabetes and its treatment; and depression and 
diabetes are highly prevalent diseases that 
coexist solely by chance (5). The results of two 
recent studies have proven the opposite 
direction that depression preceded and 
predisposed people todiabetes (6, 7), yet with 
unclear mechanism. One might argue that 
depression is often accompanied by poor 
health behaviors (i.e., smoking, physical 
inactivity, uncontrolled caloric intake) that 
risks individuals to develop type 2 diabetes (8). 
Depression is also associated to central 
obesity and impaired glucose tolerance (9). In 
addition, depression is well known to be 
linked to physiological abnormalities, including 
activation of the hypothalamic-pituitary-adrenal 
(HPA) axis, sympathoadrenal system, and pro-
inflammatory cytokines, which induce insulin 
resistance and eventually contribute to diabetes 
incidence (10). 
 
It is also becoming increasingly clear that 
the relationship between depression and 
diabetes as being different for type 1 and type 2 
diabetes (11). For example, a recent systematic 
review of the literature on depression in type 1 
diabetes found no evidence of increased rates 
of depression in people with type 1 diabetes 
(12) whereas the data in type 2 diabetes clearly 
show higher rates of depression (13). This 
indicates future direction that the therapy 
option might be different. 
 
In patients with diabetes, depression is 
associated with higher mortality and higher 
risk of major complications (14-16). 
Furthermore, patients with diabetes and 
depression reported a poorer quality of  life 
(17),  reduced  well-being (18),  higher  
diabetes-related  distress (19,  20),  lower 
diabetes treatment satisfaction (21), reduced 
diabetes self-care (22), and higher non-
acceptance of diabetes treatment modality (23). 
All of these combined would further add lethal 
effects on the outcome . 
The mechanisms explaining depression to 
increase morbidity and mortality are not fully 
understood. Not only behavioral factors such  
as  poor  self-care (22),  pro-inflammatory  
mechanisms  are also considered responsible . 
Howren et al. (24)  reported that depression 
is associated with elevated circulating levels of 
C-reactive protein and interleukin (IL) -6, serve 
as pro-inflammatory mediators, as well as 
higher levels of the counter-regulatory IL-1 
receptor antagonist (IL-1RA) (25, 26). 
Therefore, subclinical inflammation may be a 
reasonable mechanism translating poorer 
prognosis in individual with depression and 
diabetes, not surprisingly because the 
aforementioned inflammatory markers are also 
associated with diabetes complications (27). 
 
Despite the  effectiveness  of psychological 
and  psychopharmacological interventions in  
treating depressive symptoms in people with 
diabetes , their effects on glycemic control 
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remain inconsistent. In the  psychosocial or  
mixed intervention arm,  Petrak  et al. (28)  
reported that  both  cognitive behavioral 
therapy and sertraline did not improve 
glycemic control in patients with depression 
and poorly controlled diabetes. Likewise, 
Hermanns et al (29) showed that diabetes 
specific-cognitive behavioral therapy in patients 
with depression and diabetes did not improve 
HbA1c. However, both studies did show 
significant improvement in depression scale. In 
contrast, Safren et al. (30) reported that 
cognitive behavioral therapy for adherence and 
depression trial (CBT-AD trial) improved 
HbA1c, adherence, and  depression symptom  
in type  2  diabetic patients.  Similarly,  an 
integrated care intervention consisting 
education, guideline-based treatment 
recommendations and monitoring of 
adherence and clinical status demonstrated 
improvement of depression, significant 
reduction of HbA1c  level, and  better 
adherence  (31).  But,  another  systematic 
review and meta-analysis  of collaborative care 
in 2,238 diabetic patients with depression (32) 
failed to document a significant reduction of 
HbA1c le vel. This later data further 
confirmed inconsistency of psychosocial or 
mixed intervention in improving glycemic 
control. 
 
Psychopharmacological  intervention  did 
show good results in reducing depression 
symptoms in diabetic patients. However, 
variable results on glycemic control was 
observed, similar with psychosocial or mixed 
intervention. Nortriptyline (a tricyclic 
antidepressant) has led to worsening of glucose  
control  indices,  whereas  fluoxetine and  
sertraline  (both  selective  serotonin reup take 
inhibitors [SSRIs]) consistently produce 
reduction of glucose levels (33). 
Fair amount of ongoing researches is 
being awaited to better provide efficacious 
option in the treatment of depression in 
diabetes. Interestingly, CAM that has gained a 
lot of attention among patients with chronic 
diseases, is now increasingly used in treating 
patients with depression. It is now the  10  most 
frequent modalities used to treat depression 
(34).  Herbal remedies,  acupuncture, 
homeopathy,  massage,  relaxation, and  
unconventional  psychotherapeutic  approach  
have  been reported as the most prevalent 
CAM among psychiatric patients (35). 
Diabetic patients are also familiar with CAM, 
not surprisingly, because diabetes health 
professionals use or recommend CAM to 
people with diabetes. For example, Sabo et al. 
(36) surveyed 2,850 American diabetes educators 
about their CAM use and achieved a response 
rate of 829. Not only people with diabetes use 
CAM to improve glycemic control, but they 
also use it for a range of other reasons, such 
as prevention, to manage distressing symptoms 
such as pain associated with complications, and 
to improve their quality of life (37). Leese et al. 
(38) found 17 % of people with diabetes 
attending an outpatient clinic in the United 
Kingdom used CAM. Egede et al. (39) extracted 
data from a United States Medical Expenditure 
Survey and estimated that people with diabetes 
have odds of 1.6 times to use CAM than non-
diabetics and suggested that diabetes is an 
independent predictor of CAM use in people 
over 65 years. 
 
LPD as one form of CAM, has been studi 
ed extensively in Yogyakarta, Indonesia. It 
consists of the combined practices of 
relaxation and dhikr focusing on breathing 
exercise and the meaning of the words spoken 
during dhikr (repetitive prayer and guided 
imagery) as a self-management technique that 
was believed could evoke relaxation response. 
It was hypothesized that relaxation response 
would decrease stress response or depression 
symptoms , which in turn improve glycemic 
control (40). The effects of LPD on 
inflammatory mediators, metabolic marker, 
and various clinical relevance in depression 
patients with diabetes were also studied. The 
results are potentially promising, making it 
possible to target both depression and 
diabetes to improve concurrently with one key 
therapeutic approach. 
 
 
 
Current Evidence from Randomized 
Controlled Trials (RCTs): What Do We Have 
Now? 
 
As a brief example, the search of current 
RCTs (June, 2016) in PubMed database 
published for the past 
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5 years with keyword diabetes and 
depression reveal ed at least 20 results of RCT 
in diabetic patients with depression. The RCTs 
consisted of psychopharmacological 
intervention, psychosocial intervention, or 
combination of both. What we do have now is 
a broader option to effectively treat depression 
in diabetic patients, yet still with limitations 
regarding glycemic control . Some of the results 
has been cited above. Interestingly there are 
fair amount of studies consisted of only 
psychosocial interventions, whereas few studies 
addressing CAM use. 
 
Complete literature review had been 
published in 2009 by Petrak et al. (41) and in 
2011 by Markowitz et al. (42) with extensive 
discussions and details concerning each RCT. 
Therefore, we are not coming with such  a 
2016  review, but more to describe concisely 
what we have reach ed until now. The 
followings are  interventions  found in  the  
PubMed  databases:  stepped care  
interventions  (43), depression care 
management (44), algorithm-based care (45), 
multifaceted psychiatric intervention (46), 
interpersonal psychotherapy (47, 48), cognitive 
behavioral therapy (CBT) (28-30), collaborative 
care  (32,  45,  49,  50),  nurse-led case manager 
(51),  addition of fish oil to antidepressants 
(52), psychoeducation and physical exercise 
(53), integrated primary care  (31), intensive 
lifestyle intervention (54), acceptance 
facilitating intervention (55), and integrated 
care management (31). Psychopharmacological 
therapies found in PubMed include s-
citalopram (56), fluoxetine (57), paroxetine (58), 
sertraline (59), agomelatine (60), and 
nortriptyline (61). 
None of the RCTs involved CAM as the 
primary intervention, nor in combination with 
psychopharmacological or psychosocial 
intervention , except one study that evaluate 
the use of fish oil to complement 
antidepressant use (52). In contrast, patients 
with diabetes and or depression frequently use 
CAM in the out-clinic setting (34, 38, 39). 
Moreover, there are growing evidences for 
beneficial effects of CAM in depression, 
including exercise, herbal medicines (Hypericum 
perforatum), acupuncture, and relaxation 
therapies (11). Although further research 
involving RCT is still needed to better evaluate 
the effect of those modalities, the role of 
CAM  in the  setting of diabetes and 
depression cannot be ruled out. 
 
As mentioned above, LPD as one form of 
relaxation therapy under CAM appears to have 
a potential role in the treatment of diabetic 
patients with depression. Considerable amount 
of RCTs have been conducted locally in regard 
of LPD among diabetic patients with 
depression. The intervention used in most of 
the RCTs was either LPD alone or in 
combination with psychopharmacological 
intervention. To date, there are 48 studies 
published by Gadjah Mada University in 
Yogyakarta Indonesia evaluating the efficacy of 
LPD in various clinical settings, and at least 11 
of them involved diabetic patients with 
depression symptoms. 
 
 
Psychopharmacological Intervention 
 
The impact of antidepressant use on 
glucose regulation are variable, from 
hypoglycemic, hyperglycemic or neutral effects, 
depending on the specific type of the drug. 
The mechanisms are thought to be related to 
insulin sensitivity as the main effector, while 
other reports showed possible interaction with 
hypoglycemic agents (62). 
 
SSRIs have a beneficial and synergistic 
effect on both mood and HbA1c levels in 
diabetes patients with depression. An open-
label study administered sertraline at a dose of 
50 mg/day to 28 patients for a 10-week period 
(63). During that time, in addition to reducing 
the scores on the Hamilton Depression. 
 
Rating Scale (HDRS) (p < 0.001) and the 
Beck Depression Inventory ( BDI), dietary 
compliance rose (p < 
0.005), and HbA1c levels generally 
improved. More recently, a double -blind, 
placebo-controlled study was completed with 
fluoxetine (57). In that study, a maximum dose 
of 40 mg/day was received by each of 60 
participants for an 8-week period. The 
differences in response (fluoxetine vs. placebo) 
were significant for both HDRS (p = 0.01) and 
BDI ( p = 0.03). HbA1c levels improved more 
on fluoxetine than on placebo but results did 
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not reach significance. This was probably 
because the trial lasted only 8 weeks. 
 
In the other RCT of SSRI, 49 mildly 
depressed patients wit h non-optimally 
controlled type 2 diabetes patients were 
randomized to six months of paroxetine or a 
placebo (58). No significant differences in 
HADS scores between the groups was 
observed. Three months later, HbA1c levels 
were found lower in patients in the paroxetine 
than in the placebo group (p = 0.018), but 
were not maintained at six months. It is 
interesting that this study included only 
patients with non-optimally controlled diabetes 
so that the opportunity to demonstrate 
improvement in glucose control could be 
potentiated, and at least, satisfyingly explained 
the difference observed between groups. 
 
Another recently published open-label 
study of SSRI treatment diabetes patients with 
depression has been conducted (56). 
Researchers gave patients with comorbid 
major depression (assessed by the Structured 
Clinical Interview for DSM Disorders [SCID] 
and HDRS score ≥ 16) and type 1 or type 2 
diabetes, an open-label s-citalopram therapy for 
up to 16 weeks. A significant reduction in mean 
HDRS scores and a limited non-significant 
decrease in HbA1c levels ( –0.36%) was 
observed. This adds more information 
regarding the effectiveness of SSRIs in 
depressed diabetic patients, though without 
control group the re sults need more 
replications and extensions. 
 
In relation with hypoglycemia, nefazodone, 
an antidepressant that can  block 5-HT  
reuptake but predominantly appears to act by 
blocking postsynaptic 5-HT receptors, has been 
reported to produce hypoglycemic attacks that 
led to a reducti on in insulin dosage by 15% 
(64). Another antidepressant called 
monoamine oxidase inhibitors (MAOIs), as 
shown in case reports back in 1960,  can 
cause extreme hypoglycemic episodes (65). 
Other agent, the noradrenergic antidepressant, 
maprotiline, has also been shown to cause 
hypoglycemia even at low doses, which was 
consistent with the laboratory studies (66). 
Fluoxetine has also been shown through case 
report to cause hypoglycemia, hypoglycemia 
unawareness, and increased insulin sensitivity 
(62). Another SSRI, sertraline, has been 
demonstrated to reduce postprandial 
hyperglycemia in rats and to induce the 
hypoglycemic effects of sulfonylurea agents in 
humans. It has not been reported to cause 
hypoglycemia independently, but in a case 
report by Pollak et al . (67), a non-diabetic patient 
with multiple episodes of hypoglycemia during 
sertraline therapy, had resolved after 
discontinuation of sertraline . 
 
Nortriptyline, on the other hand, was shown 
to have a potentially antagonistic effect; while it 
improves depressive symptoms, it adversely 
affect glucose control by promoting 
hyperglycemia (61). Imipramine administration, 
in a series of case rep orts in 1960,  showed 
that although short-term dosing led to a fall in 
FPG, long-term administration significantly 
increased baseline values of fasting plasma 
glucose (25). 
 
There was one published study of another 
antidepressant in patients with diabetes and de 
pression. Lustman et al. (68) administered an 
open-label bupropion for 10 weeks to the 
enrolled 93 patients with type 2 diabetes and 
major depression; the depression was remitted 
in 63 patients (84%) whom then were followed 
for an additional 24 weeks. It was found that 
Body Mass Index (BMI), body fat, and HbA1c 
levels decreased significantly in the first 
attempt, and that these changes maintained 
during follow-up. 
 
While antidepressants may have an 
important role to play in the treatment of 
depression in diabetes, there is also some cause 
for concern. Use of anti -depressant 
medications was shown to be associated with 
increased risk of developing diabetes who are 
alre ady at elevated risk for diabetes (overweight, 
high fasting glucose, and impaired glucose 
tolerance) (69). Antidepressant use was also 
shown to be related to  cardiovascular  disease 
risk factors  (e.g., e levated blood  pressure 
and  dyslipidemia), independent of depression 
symptoms (70). This warrants precaution of 
using antidepressants, not only the  short term 
side effects that deserve more  attention, but 
also the  long term  risks  on cardiovascular 
and diabetes outcome. 
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Complementary Alternative Medicine in 
Depression and Diabetes 
 
The term „complementary therapies‟ is 
actually an umbrell a term that encompasses 
more than 300 different modalities. It tends to 
diverse and encompasses various health 
practices or approaches, which are self-defined 
by the users and applied on their own or in 
combination with conventional medicines. The 
two systems can be separate with one system 
dominant but also they can complement each 
other (37). 
 
According  to WHO,  traditional medicine 
was  defined as  “diverse health practices, 
approaches, knowledge  and beliefs  
incorporating  plant,  animal,  and/or  mineral 
-based  medicines,  spiritual therapies, manual 
techniques and exercise applied singularly or 
in comb ination to maintain well-being, as  
well as  to treat,  diagnose or  prevent 
illness ”. Thus, the  terms “complementary” 
and “alternative” (and sometimes also “non-
conventional” or “parallel”) are used to refer to 
a broad set of health care practices that are 
not part of a country‟s own tradition, or not 
integrated into its dominant health care system 
(71). 
 
As well as a range of definitions of CAM, 
there is a range of ways they are categorized or 
grouped. For example, the US NIH, as cited by 
Pawa (37), divided CAM into five main 
categories: 
 
1. Alternative medical systems such as 
Chinese medicine and Ayurveda. Chinese 
medicine was known as „traditional 
Chinese medicine‟ until recently. 
2. Mind–body therapies. 
3. Biological-based   systems   such   as   
herbal   medicine,  which  is   s ometimes  
known  as phytomedicine 
4. Chinese, Kampo (Japanese), Ayurveda 
(India), North American Indian, and 
European. 
5. Manipulative and body therapies such as 
massage and chiropractic. 
6. Energy therapies. 
 
Until recently there has been limited quality 
research into complementary medicine, 
because, as in other areas, funding is difficult 
to access, research expertise and research 
mentors are lacking, and there is limited 
infrastructure to support research. A great deal 
of the available research is difficult to interpret 
due to methodological flaws, poor reporting, 
and a great deal is not conducted in the manner 
the particular therapy is practiced (72). 
 
Despite those limitations, Ernst et al. (73) 
reported depression is one of the most 
common reasons people use CAM. Meanwhile, 
Egede et al. [37] estimated that people with 
diabetes are 1.6 times more likely to use CAM 
than non-diabetics and suggested that diabetes 
is an independent predictor of CAM use in 
people over 65 years. To date, although there 
are numbers of trials addressing CAM in 
treating diabetes alone or depression alone, 
there are only few RCTs, if any, addressing 
CAM in the treatment of both diabetes and 
depression as one entity. Electronic database 
search through PubMed and Cochrane Library 
conducted in June 2016  found no result for 
RCT in depressive diabetic patients. However, 
some limited RCT can be found in some 
internet literature, consisting of small sized 
study and negative results. 
 
For example, a stress management and 
relaxation program was evaluated through 
randomized, wait- list controlled study by 
Stenstrom et al . (74). Participants were people 
with type 1 diabetes who were considered as 
having stress-related difficulties in their daily 
life and in the management of their diabetes 
(n = 36). The study delivered 14 sessions of 
two-hour group meetings, where instructions in 
stress and stress management, muscle 
relaxation, mental imaging, and mental goal 
setting were practiced. There were noted i 
mprovements in relaxation and tension with 
the greatest for those having poorest scores at 
baseline. No improvements in mood or HbA1c 
were reported. 
 
Similar results were also noted by Surwit et 
al. (75) in subjects with type 2 diabetes (n = 108). 
A control group (n = 48) who received five 
weekly group sessions of diabetes education, 
was compared to experimental group (n = 60)  
practicing five sessions of stress management 
training (consisted of progressive muscle 
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relaxation [PMR] , skill developing instruction 
through stress-reducing cognitive and 
behavioral therapy, and education about the 
impact of stress to individual‟s health). Over 
period of six months, there was no difference 
in HbA1C improvement between groups. At 
the subsequent 
12-months follow up, improvements were 
only sustained in the stress m anagement 
group with a 
significant 0.5% reduction in HbA1C. The 
study found no effect of intervention on 
perceived stress, anxiety, and general 
psychological health. 
Both of the above study did not 
specifically mention that the subject had well 
defined depression, nevertheless, they did 
mention that the stress management 
intervention reduce the stress level but not 
HbA1c. If CBTs satisfied the criteria of CAM, 
then the results of RCT of CBT ran in the 
parallel way with stress management therapy 
(28-30). The results were also in accordance with 
the review formerly stated regarding 
psychopharmacol ogical intervention that they 
favor depression but not consistently glycemic 
control. Given the lack of RCTs addressing 
CAM use among depressive diabetic patients, 
the field of research in this topic is still widely 
open. 
 
 
 
Latihan Pasrah Diri (LPD) 
 
LPD consists of the combined practices of 
relaxation and dhikr focusing on both 
breathing exercise and the meaning of the 
words spoken during dhikr (re petitive prayer 
and guided imagery) as a self- management 
technique that was believed could evoke 
relaxation response. It was hypothesized that 
relaxation response would decrease stress 
response or depression symptoms, which in 
turn improve glycemic control (40). 
 
LPD as a method of relaxation was first 
introduced to solely treat depression. But now, 
many of the post graduate students of internal 
medicine in Gadjah Mada University Yogyakarta 
interested to study LPD in more extended 
fashion. As documented in the library of 
Gadjah Mada University, there are increasing 
number of studies examine the effect of LPD, 
not only to depression, but also to the natural 
course of chronic diseases often accompanying 
depression, such as diabetes, chronic kidney 
disease, human  immunodeficiency virus  
(HIV)  infection,  cancer,  chronic obstructive  
pulmonary disease, hypertension, geriatric 
malnutrition, and many others. 
 
To mention, LPD was also introduced with 
religious nuance. The fact that people tend to 
choose CAM that are congruent with their 
personal values and beliefs (34) leaves LPD the 
most suitable approach to be used in religious 
society. Especially in Indonesia, where the 
citizens tend to practice Islamic belief in their 
daily living, LPD unite well with it, not 
surprisingly, because it consists of repetitive 
prayer that was long recognized in Isl am as 
dhikr. Although intercessory prayer has been 
shown to have no significant effect on medical 
outcomes after hospitalization in a coronar y 
care unit (76), it may not be the same with the 
effect of dhikr performed during LPD to the 
depressive diabetic patients. At least until now, 
there is no evidence against its usefulness. 
 
LPD has another component called guided 
imagery. This component attempts to help 
people enter into a relaxed state by trying to 
mentally place themselves in a different 
situation. In Islamic belief, the same technique 
is performed during salat, the five times prayer 
they always perform as the highest obligation for 
Moslems to worship Allah, God of the Universe. 
When performing salat, Moslems were taught 
to consider their selves as if they met Allah 
directly in a heavenly place. In LPD, patients 
are taught the same method that they should 
think and feel like they were in a paradise, 
releasing all of their sorrows and replace them 
with positive energy originating from Allah. 
The instructor of LPD can help the  individual 
through  the  process,  by prompting the m to  
imagine, and encouraging the individuals to 
place themselves in such heavenly place with 
increasing accuracy, by reminding them of the 
sounds, sights, smells, and feelings that go 
with paradise. Because in Islam, the description 
of paradise is given in great details that every 
Moslem must have known before, the 
instructor seldom find difficulty to assist the 
moslem patients. The same thing might apply 
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to religious non -moslem patients. With time 
and practices, the individual will not need to 
use the gui dance provided by the instructor. 
Guided imagery is a widely used technique, 
including in the large prospective cohort of 
Chronic  Disease  Self-Management  Program  
conducted  to  help  individuals develop  
their  self-management skills (77). The cohort  
showed positive results in various outcome, 
underlining the effectiveness of guided imagery 
in the patient management. 
 
Breathing exercise is also part of LPD. The 
breathing exercise consists of inhaling, holding, 
and exhaling breath in a timely manner. It is 
hypothesized that by holding breath, the 
partial carbon dioxide pressure in blood will 
transiently increase, and this gives vasodilating 
effect in the brain circulation which in turn 
mediate the relaxation state in the body. By 
closing the eye, this technique is done 
simultaneously with guided imagery, where 
exhaling breath equal to releasing a ll of the 
sorrows out of the individual‟s life. One 
session of LPD consists of 15 – 20 minutes (21 
cycle of breathing exercise combined with 
dhikr and  guided imagery)  2  times a  day.  
It  is recommended that  LPD  to  be 
continuously practiced for at least 21 days in 
order to achieve the expected result. 
 
Dharma (40) reported insignificant decrease 
of fasting plasma glucose with 2 session/day 
LPD for 21 days among diabetic patients with 
depression symptoms compared to controls ( n 
= 36, p = 0,055). However, the fructosamin 
level was decreased significantly in LPD group 
(p = 0,01). BDI score were also decreased but 
failed to reach significance level (p = 0,06). On 
the contrary, Muin (78) reported that 
fructosamin level was not decreased 
significantly in LPD plus fluoxetine group 
compared to fluoxetine alone group (p =0.902), 
and neither was the BDI score (p = 0.437). 
 
The effect of LPD in inflammation 
parameter among depressive diabetic patients 
was also studied. Rudiansyah (79) and 
Kusbandono (80) found that LPD had variable 
effect on C-reactive protein (CRP) level in 
diabetic patients with depression symptoms. 
Meanwhile, Widodo (81) reported that leucocyte 
count was insignificantly lower in LPD group 
compared to control. Nevertheless, the 
researchers reported significant improvement 
of BDI score in LPD group compared to 
control , save Kusbandono. The influence of 
LPD to other mediators such as e ndotheline-1 
and nitrous oxide among depressive diabetic 
patients was  also  evaluated in two other 
RCTs  (82,  83).  Both  mediators were  shown 
insignificantly lower in the LPD plus 
fluoxetine group compared to fluoxetine alone 
group. A larger trial is needed to confirm all of 
these insignificant results. 
 
In another report, LPD was able to 
significantly lower blood pressure and pulse 
frequency (84), a sign of good relaxation 
responses. LPD was also demonstrated to 
improve quality of life (assessed with diabetes 
quality of life clinical trial questionnaire-revised 
score) and showed positive effect to lower BDI 
score among depressive diabetic patients (85). 
 
Astin et al. (86) reported potential adverse 
effects regarding relaxation technique, including 
intrusive thoughts, fear of losing control, muscle 
cramps, and spasms. It is postulated that adverse 
effects came from underprepared individual. 
Dharma (40) documented 3 out of 18 subjects 
in his study (15%) had adverse effects during 
early phase of LPD. The adverse effects 
reported were autogenic discharge (anxiety, 
dyspnea, palpitation, pain, and elevated blood 
pressure) which also had previously been 
documented and described by Zalaquett and 
McGraw (87). Adverse effect may occur 
probably due to the lack of knowledge 
regarding the proper technique to perform LPD. 
 
The RCTs evaluating LPD in diabetic 
patients with depression were still limited by 
the lack of power (high rate of false negative 
result due to small sample size ), difficulty of 
standardization and funding, incompliance 
subjects, and some methodological flaw. Once 
these limitations removed, we might expect 
that LPD would become a therapy of interest, 
not only because it is simple and far from 
expensive, but also the religious nuance that 
makes people tend to believe that Allah 
Himself, God of Almighty, directly send the 
healing to the patients. 
 Conclusion 
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The problem of depression in diabetic 
patients has come into existence and the 
treatment is expected to  improve both  
depression and  diabetes. Despite the  
effectiveness of  available treatments in 
reducing  depression in  diabetes, no  
consistent effects in  HbA1c  levels were 
observed. While antidepressants may 
contribute as a key role in the treatment of 
depression in diabetes, still some cause for 
concern remains. They may risk patients to 
cardiovascular disease or worsening of glycemic 
control (including hyperglycemia or 
hypoglycemia). In contrast, psychosocial 
interventions or CAM, used alone or in 
combination with antidepressants , variably 
showed its beneficial effects on both 
depression and diabetes. To date, the studies 
regarding CAM in both depression and 
diabetes are lacking. LPD as a form of CAM 
introduced in 2005,  is still being extensively 
studied in Yogyakarta Indonesia. It began to 
show its efficacy in multiple RCTs conducted 
since 2006.  Although the RCTs evaluating 
LPD in diabetic patients with depression were 
still limited by the lack of power (small sized 
sample), difficulty of standardization and 
funding, incompliance subjects, and some 
methodological flaw, the potential role of LPD 
remains to be elucidated. The field of research 
is still widely open, and more researchers with 
well-designed trial concept are welcome. 
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